Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study-Reference-Cited by-同舟云学术

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Published:2017-02 Issue:2 Volume:5 Page:107-118
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Konstan Michael W,McKone Edward F,Moss Richard B,Marigowda Gautham,Tian Simon,Waltz David,Huang Xiaohong,Lubarsky Barry,Rubin Jaime,Millar Stefanie J,Pasta David J,Mayer-Hamblett Nicole,Goss Christopher H,Morgan Wayne,Sawicki Gregory S

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference30 articles.

1. Cystic fibrosis;Elborn;Lancet,2016

2. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis;Konstan;J Pediatr,2003

3. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis;Konstan;J Pediatr,2007

4. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis;Corey;J Pediatr,1997

5. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients;Schluchter;Stat Med,2002

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metagenomics Applied to the Respiratory Mycobiome in Cystic Fibrosis;Mycopathologia;2024-09-12

2. New Therapies in Outpatient Pulmonary Medicine;Medical Clinics of North America;2024-09

3. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report;Annals of the American Thoracic Society;2024-09

4. Synthesis and Biological Evaluation of Pyrazole–Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR);Journal of Medicinal Chemistry;2024-08-13

5. A reproduced combination of ivacaftor and lumacaftor, CFTR protein modulators. Ethical and pharmacokinetic aspects;Медицинская этика;2024-06